Website changes

The Pipeline segment of the Noxopharm website has been updated, with content added for:

Our Technology - http://www.noxopharm.com/irm/content/our-technology.aspx?RID=472
Clinical Overview - http://www.noxopharm.com/irm/content/clinical-overview.aspx?RID=489
Clinical Studies - http://www.noxopharm.com/irm/content/clinical-studies.aspx?RID=490

Another section that is worth re-reading is http://www.noxopharmblog.com.au/ceo-blog-patent-application-process-explained/, in which Graham Kelly points out that the most important patent applications have been lodged but are not yet in public view.  These applications illustrate why NOX66 works and I expect that they will for the first time (in patent terms) introduce Idronoxil-C, a new version of Idronoxil that is novel and patentable.

Note that Idronoxil-C was first mentioned in a Blog on 30 March 2017, which means that the patent applications must have been lodged before then.
Q. What is idronoxil-C?
A. Idronoxil-C is an exciting development that we believe has increased very considerably the value of the Company’s IP assets, opening up some potentially very important therapeutic and commercial opportunities.
When we dose with NOX66, the idronoxil is absorbed into the body and appears in the blood in various forms. This is something that happens with most drugs that humans take.  In the case of idronoxil, some of these forms are inactive. But we have discovered one very distinctive form that we refer to as idronoxil-C that we believe is the main active form. This is a novel (and patentable) form of idronoxil.
Q. What is so exciting about discovering idronoxil-C?
A. Two main reasons. The first is that when it comes to seeking approval to market a new drug such a NOX66, understanding how the product is working helps the approval process considerably. It’s not essential to know everything about how a drug is working to get marketing approval, but it helps.
The second is that we have identified what essentially is a new drug. It’s still idronoxil, but it’s idronoxil in a form that makes it work better, and that opens up a wide range of opportunities.
From here we either can give patients idronoxil-C indirectly (via NOX66), or directly (pure idronoxil-C products). Our strategy is to develop both, with the indirect route (NOX66) our current focus.​